Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
iShares U.S. Pharmaceuticals ETF (IHE) and Invesco Dynamic Pharmaceuticals ETF (PJP) belong to the same industry segment: US Health Care. Both ETFs have the same top 3 sector exposures: and Health Care. IHE is less expensive with a Total Expense Ratio (TER) of 0.38%, versus 0.57% for PJP. IHE is up 4.3% year-to-date (YTD) with +$129M in YTD flows. PJP performs worse with 0.96% YTD performance, and +$89M in YTD flows. Run a side-by-side ETF comparison of IHE and PJP below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | IHE PJP | -1.82%-3.66% | +5.93%+0.35% | +4.30%+0.96% | +28.47%+25.49% | +63.32%+46.89% | +61.21%+39.70% |
| Flows | IHE PJP | +$9M+$6M | +$154M+$93M | +$129M+$89M | +$248M+$91M | +$359M+$6M | +$393M-$49M |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | IHE PJP | +15.86%+14.70% | +20.40%+18.60% | +15.94%+15.30% | +15.80%+15.87% |
| Max drawdown | IHE PJP | -4.49%-5.17% | -14.18%-13.71% | -16.04%-16.11% | -16.12%-17.41% |
| Max drawdown duration | IHE PJP | 10d31d | 150d130d | 210d275d | 669d788d |
IHE | PJP | |
Last sale 3/12/2026 at 1:46 PM | $87.05 | $103.91 |
| Previous close 03/11/2026 | $88.40 | $105.46 |
| Consolidated volume 03/11/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
IHE | PJP | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
IHE | PJP | |
|---|---|---|
| Last price | $87.05 | $103.91 |
| 1D performance | -1.53% | -1.47% |
| AuM | $1.02 B | $406.31 M |
| E/R | 0.38% | 0.57% |
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
